Nevertheless, the negative immunoreactivity for BRAF V600E in all cases indicates that the combination of morphological analysis with immunohistochemistry may improve the prediction for thyroid carcinoma harboring the RET and/or NTRK fusion genes. This evidence concerns the gene BRAF and thyroid gland carcinoma.